GlassScriptPhysician profile
Djahna Thomas
NPI 1629238555
$2,259.80
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $1,551 · 2022: $13.25 · 2023: $37.76 · 2024: $21.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.32 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.32 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,378.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $244.34 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $179.73 | 2019-2023 | Dupixent |
| Glaxosmithkline, LLC. | $134.12 | 2019-2020 | |
| Alk-Abello, INC | $54.56 | 2019-2020 | |
| Kaleo, INC. | $52.76 | 2019 | |
| Optinose US, INC. | $46.15 | 2019 | |
| Pfizer INC. | $44.62 | 2019-2023 | |
| Genzyme Corporation | $37.10 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $35.08 | 2022-2024 | Orladeyo |
| Mylan Pharmaceuticals INC. | $15.85 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.25 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.34 | 2019 | |
| Phadia US INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Djahna Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.